<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; IPXL</title>
	<atom:link href="http://www.stockbloghub.com/tag/ipxl/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Beats Earnings Expectations &#8211; Increases Earnings Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674</link>
		<comments>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:52:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58674</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per ADS. Higher revenues accounted for the strong performance. Revenues Quarterly revenues increased 31% year over year to $874 million, well above the Zacks Consensus Estimate of $847 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 32% to $794 million, while royalties increased 27% to $76.5 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR, 3TC and Zeffix. During the third quarter, Shire received royalties from Impax Laboratories Inc. (IPXL) for Adderall XR and from GlaxoSmithKline plc (GSK) for 3TC and Zeffix. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BA) Stock Market News for August 24, 2010</title>
		<link>http://www.stockbloghub.com/2010/08/24/ba-stock-market-news-for-august-24-2010/49147</link>
		<comments>http://www.stockbloghub.com/2010/08/24/ba-stock-market-news-for-august-24-2010/49147#comments</comments>
		<pubDate>Tue, 24 Aug 2010 20:16:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aerospace-Defense - Major Diversified]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[3PAR]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BIG]]></category>
		<category><![CDATA[Big Lots Inc.]]></category>
		<category><![CDATA[BKC]]></category>
		<category><![CDATA[BlackRock]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Burger King Holdings Inc.]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PAR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49147</guid>
		<description><![CDATA[U.S. stocks dropped on Monday as economic worries prevailed over early-morning enthusiasm resulting from Hewlett’s Packard’s bid for 3Par. The takeover tussle for 3Par sent technology shares almost to the bottom of the decliners’ list as investors rushed to safe havens and defensive stocks. Hewlett-Packard’s (NYSE:HPQ) shares fell 2% after the computer maker offered to buy data storage company 3Par (NYSE:PAR), rivaling a prior offer from Dell Inc. (NASDAQ:DELL). All stock indexes fell on the day, led by a 0.9% drop in tech-heavy Nasdaq. H.P. said it will pay $1.6 billion for 3Par. The Dow industrials, up 91 points at one time, closed with a loss of 39 points, or 0.4%, at 10174.41. The broader S&#38;P 500-stock index fell more than 4 points, or nearly 0.4%, to 1067.36. On the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/24/ba-stock-market-news-for-august-24-2010/49147/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Drug ProAmatine&#8217;s Approval to be Withdrawn by US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619</link>
		<comments>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:28:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48619</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension). The drug was approved under the FDA’s accelerated approval program, under which companies are required to conduct post-approval studies of the drug in order to confirm its benefits. The regulatory body noted that since the time of the approval of ProAmatine, neither Shire nor the drug’s generic makers conducted studies that proved the drug’s efficacy in patients suffering from orthostatic hypotension. Shire, in response, issued a press release saying that it had conducted post-approval trials for ProAmatine as required by the FDA, but the regulatory body found those studies inconclusive asking Shire to carry out additional trials to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories Settles Dispute with Teva Pharmaceutical Industries</title>
		<link>http://www.stockbloghub.com/2009/12/03/abt-abbott-laboratories-inc-settles-dispute-with-teva-pharmaceutical-industries/21864</link>
		<comments>http://www.stockbloghub.com/2009/12/03/abt-abbott-laboratories-inc-settles-dispute-with-teva-pharmaceutical-industries/21864#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:42:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21864</guid>
		<description><![CDATA[In a filing with the U.S. Securities and Exchange Commission (SEC), Abbott Laboratories Inc. (ABT) announced that it has settled its patent litigation with Teva Pharmaceutical Industries Ltd. (TEVA), which was seeking to market generic versions of Abbott’s TriCor. According to the agreement between the companies, Teva will be allowed to launch a generic version of TriCor no sooner than March 28, 2011. However, under certain unspecified circumstances, Teva might not receive such rights until July 1, 2012. Additional details were not provided. The settlement involves the 145 mg dose of TriCor, which accounts for a major part of TriCor&#8217;s sales. Abbott’s cardiovascular business is being driven by TriCor, a powerful triglyceride lowering agent often used in-combination with statins, and its next-generation candidate, TriLipix. Given the generic threats to TriCor, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/abt-abbott-laboratories-inc-settles-dispute-with-teva-pharmaceutical-industries/21864/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Top Performer for Thurs: Par Pharmaceutical Companies</title>
		<link>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743</link>
		<comments>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743#comments</comments>
		<pubDate>Thu, 15 Oct 2009 22:29:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17743</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session. In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days. The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000. Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today&#8217;s Zacks #1 Rank List: Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HITK) Top Performer for Wed: Hi-Tech Pharmacal- Zacks #1 Rank Top Performers</title>
		<link>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354</link>
		<comments>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:53:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com.php5-2.dfw1-2.websitetestlink.com/?p=16354</guid>
		<description><![CDATA[Hi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal first quarter, leading to a sharp earnings surprise and large revenue growth. With a gain of only around 3.8%, HITK is a top-performing Zacks #1 Rank company today. Volume is at 514,000, versus the daily average of 586,000. HITK is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. It specializes in difficult-to-manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The company is part of the Medical-Generic Drugs industry. There is only 1 other name from that space on today&#8217;s 218-stock Zacks #1 Rank List, and that is Impax Laboratories, Inc. (IPXL). Strong Fiscal First Quarter In early September, HITK ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

